Eisai Co. Licenses Protein Expression Data Analysis System from Rosetta Biosoftware
News Jan 03, 2007
Eisai Co. will be using the Elucidator system in the Laboratory of Seeds Finding Technology to support LC-MS quantification methods for identifying potential neurology biomarkers.
“The Elucidator system will be an important tool for enabling quantitative methods and characterizing cancer proteomes by multidimensional LC-MS/MS,” said Yoshiya Oda, Ph.D., senior scientist at the Laboratory of Seeds Finding Technology.
“We are honored to provide the Elucidator system to this prestigious pharmaceutical company,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.
“The Elucidator system supports end-to-end data management and analysis workflow for comparative proteomics, and provides multiple ways for scientists to analyze and refine their data to achieve high-confidence results.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.